Midostaurin treatment in systemic mastocytosis patients has shown that patients with one or more mutations in the S/A/R (SRSF2, ASXL, or RUNX1) panel have a lower survival rate and a higher progression rate to AML or mast cell leukemia than patients without mutations. The gene discussed is SRSF2; the disease is mast cell leukemia.